Brief: Syndax Announces Topline Results From Maxpire Phase 2 Trial Of Axatilimab In Idiopathic Pulmonary Fibrosis
12/10/2026 22:29
BRIEF-Syndax Announces Topline Results From Maxpire Phase 2 Trial Of Axatilimab In Idiopathic Pulmonary Fibrosis Oct 12 (Reuters) - Syndax Pharmaceuticals, Inc. SNDX.O:
SYNDAX ANNOUNCES TOPLINE RESULTS FROM MAXPIRE PHASE 2 TRIAL OF AXATILIMAB IN IDIOPATHIC PULMONARY FIBROSIS
SYNDAX PHARMACEUTICALS - WILL NOT PURSUE FURTHER DEVELOPMENT OF AXATILIMAB IN IPF
SYNDAX PHARMACEUTICALS - AXATILIMAB WELL TOLERATED WITH NO NEW SAFETY SIGNALS IN MAXPIRE TRIAL
SYNDAX PHARMACEUTICALS - AXATILIMAB CONTINUES IN MULTIPLE CGVHD TRIALS WITH RESULTS EXPECTED LATER THIS YEAR AND EARLY 2028
SYNDAX PHARMACEUTICALS - MAXPIRE PHASE 2 TRIAL OF AXATILIMAB IN IPF DOES NOT MEET PRIMARY ENDPOINT
Source text: ID:nGNXCm0gG
Further company coverage: SNDX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Syndax Pharmaceuticals
See all newsBrief: Syndax Announces Topline Results From Maxpire Phase 2 Trial Of Axatilimab In Idiopathic Pulmonary Fibrosis
Syndax says mid-stage trial of lung disease treatment fails main goal, ends development
Syndax Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Syndax Q2 revenue jumps 92% on Revuforj, Niktimvo demand
Brief: Syndax Pharmaceuticals Q2 Operating Income USD -39.995 Million